Lebrikizumab: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Lebrikizumab appears in the FDA drug-label database. Marketed as EBGLYSS.
- Drug class
- Interleukin-13 Antagonist (FDA established pharmacologic class)
- Mechanism of action
- Interleukin-13 Antagonists (as stated on the FDA label)
FDA-approved use
EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. EBGLYSS ® is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. ( 1 )
Phase breakdown
Conditions being studied
| Condition | Trials |
|---|---|
| Eczema · Lebrikizumab for Eczema | 3 |
| Atopic Dermatitis | 2 |
| Nummular Eczema | 1 |
| Psoriasis | 1 |
Recruiting trials involving Lebrikizumab
- A Study of Lebrikizumab in Adults With Nummular Eczema
- Lebrikizumab in Moderate-to-severe Atopic Dermatitis
- Molecular Signatures in Inflammatory Skin Disease
Common questions
Is Lebrikizumab FDA-approved?
Yes, marketed as EBGLYSS.
How many recruiting trials involve Lebrikizumab?
3 recruiting trials across 4 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.